Abstract
Hepatitis B virus (HBV) infection has been reported to be associated with inferior prognosis in hepatocellular and pancreatic carcinoma cases, but has not been studied with respect to non small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic significance of HBV infection in advanced NSCLC patients. A retrospective cohort of 445 advanced NSCLC patients was recruited at our hospital from January 1, 2003 until August 30, 2014. Serum HBV markers were tested by enzyme-linked immunosorbent assay. COX proportional hazards analysis was used to evaluate associations of HBV infection with overall survival (OS). Of 445 patients who were qualified for the study, 68 patients were positive for HBsAg, also considered as HBV infection. Patients in HBsAg negative group were found to have better OS (12.6 months [12.2-12.9]) than those in HBsAg positive group (11.30 months [10.8-11.9]; p=0.001). Furthermore, COX multivariate analysis identified HBV infection as an independent prognostic factor for OS (HR 0.740 [0.560, 0.978], p=0.034). Our study found that HBsAg-positive status was an independent prognostic factor for OS in patients with advanced NSCLC. Future prospective studies are required to confirm our findings.
Highlights
Materials and MethodsDue to high prevalence of hepatitis B virus (HBV) infection and cancer in some developing countries, especially China, concurrent infection with Hepatitis B virus (HBV) is not uncommon in cancer patients (Sun et al, 2002; Lu et al.,2010; Xie et al, 2012; She et al, 2013; Deng et al, 2014; Liu et al, 2014)
Our study found that hepatitis B surface antigen (HBsAg)-positive status was an independent prognostic factor for overall survival (OS) in patients with advanced non small cell lung cancer (NSCLC)
Based on HBsAg status, 445 patients were divided into two groups, HBsAg positive and negative groups. 68 patients were assigned to the HBsAg-positive group
Summary
Materials and MethodsDue to high prevalence of hepatitis B virus (HBV) infection and cancer in some developing countries, especially China, concurrent infection with HBV is not uncommon in cancer patients (Sun et al, 2002; Lu et al.,2010; Xie et al, 2012; She et al, 2013; Deng et al, 2014; Liu et al, 2014). It has been shown that that HBV reactivation is a welldescribed complication in hepatitis B surface antigen (HBsAg) positive cancer patients after chemotherapy, including advanced non small cell lung cancer (NSCLC), resulting in considerable morbidity and mortality (Yeo et al, 2006; Hoofnagle et al, 2009; Chen et al, 2012; Tang et al, 2013; Lin et al, 2014).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
